The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy

Por Sherstin T. Lommatzsch, Jennifer L. Taylor-Cousar
Publicado em 2019-04-01

Therapeutic use of dendritic cells to promote the extranodal priming of anti-tumor immunity

Por Lu eChen, Kellsye L. Fabian, Jennifer L. Taylor, Walter J. Storkus
Publicado em 2013-11-01

Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice

Por Kellsye Paula L. Fabian, Nina Chi-Sabins, Jennifer L. Taylor, Ronald Fecek, Aliyah Weinstein, Walter J. Storkus
Publicado em 2017-03-01

Early Identification of Fragile X Syndrome through Expanded Newborn Screening

Por Katherine C. Okoniewski, Anne C. Wheeler, Stacey Lee, Beth Boyea, Melissa Raspa, Jennifer L. Taylor, Donald B. Bailey
Publicado em 2019-01-01

Circulating type-1 anti-tumor CD4+ T cells are preferentially pro-apoptotic in cancer patients

Por Amy K. Wesa, Maja eMandic, Jennifer L. Taylor, Stergios eMoschos, John M. Kirkwood, William W. Kwok, James Harold Finke, Walter J. Storkus
Publicado em 2014-09-01

Blood mRNA biomarkers distinguish variable systemic and sputum inflammation at treatment initiation of inhaled antibiotics in cystic fibrosis: A prospective non-randomized trial.

Por Silvia M Caceres, Linda A Sanders, Noel M Rysavy, Katie R Poch, Caroline R Jones, Kyle Pickard, Tasha E Fingerlin, Roland A Marcus, Kenneth C Malcolm, Jennifer L Taylor-Cousar, David P Nichols, Jerry A Nick, Matthew Strand, Milene T Saavedra
Publicado em 2022-01-01